SecBot SecBot
SECBOTREPLAY Home › Report › KALV

KALV · Chiesi Farmaceutici will acquire KalVista for $27.00 per share in cash,…

KalVista Pharmaceuticals, Inc. · 8-K filed Apr 29, 2026 at 08:30 ET

At the news

BULLISHIMPACT 8/10

8-K filed Apr 29, 2026 at 08:30 ET

Chiesi Farmaceutici will acquire KalVista for $27.00 per share in cash, valuing the company at approximately $1.9 billion. The offer represents a 36% premium to the 30-day VWAP, and the transaction is expected to close in Q3 2026, subject to regulatory approvals and minimum tender conditions.

  • Offer price: $27.00 per share in cash
  • Total equity value: ~$1.9 billion
  • 36% premium to 30-day VWAP as of April 28, 2026
  • Transaction not subject to financing condition

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access